Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib

The Bruton tyrosine kinase (BTK) inhibitor ibrutinib improves patient outcomes in chronic lymphocytic leukemia (CLL); however, some patients experience adverse events (AEs) leading to discontinuation. Acalabrutinib is a potent, covalent BTK inhibitor with greater selectivity than ibrutinib. We evalu...

Full description

Saved in:
Bibliographic Details
Published in:Blood Adv
Main Authors: Awan, Farrukh T., Schuh, Anna, Brown, Jennifer R., Furman, Richard R., Pagel, John M., Hillmen, Peter, Stephens, Deborah M., Woyach, Jennifer, Bibikova, Elena, Charuworn, Prista, Frigault, Melanie M., Hamdy, Ahmed, Izumi, Raquel, Linghu, Bolan, Patel, Priti, Wang, Min Hui, Byrd, John C.
Format: Artigo
Language:Inglês
Published: American Society of Hematology 2019
Subjects:
Clinical Trials and Observations
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6517672/
https://ncbi.nlm.nih.gov/pubmed/31088809
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018030007
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items